<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101190</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-106</org_study_id>
    <nct_id>NCT02101190</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment</brief_title>
  <official_title>Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients
      with moderate chronic hepatic impairment and in matched healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, single-dose, parallel-group, in-patient, nonrandomized study
      conducted in 8 patients with moderate chronic hepatic impairment and in 8 healthy matched
      subjects matched by origin, age, sex, weight, and smoking habits.

      Each hepatic impaired patient and matched healthy subject participated in the study for
      approximately one month, including a 21-day screening period and a 4-day/4-night inpatient
      period. The inpatient period covered the period from Day -1 to Day 4 morning (through 72
      hours after administration). The final study evaluation was performed for all subjects in the
      morning of the day of discharge, Day 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration of BIA 9-1067</measure>
    <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
    <description>BIA 9-1067 Cmax following a single dose of 50mg BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Reach Cmax</measure>
    <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
    <description>BIA 9-1067 Tmax following a single dose of 50mg BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC0-t)</measure>
    <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
    <description>BIA 9-1067 AUC0-t following a single dose of 50mg BIA 9-1067</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 - Hepatic impaired subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 - healthy subjects treated with BIA 9-1067</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>Opicapone, OPC</description>
    <arm_group_label>Group 1 - Hepatic impaired subjects</arm_group_label>
    <arm_group_label>Group 2 - Healthy subjects</arm_group_label>
    <other_name>Opicapone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          1. Men or non-lactating and non-pregnant women,

          2. Women of non-childbearing potential (WONCBP), expected to be surgically sterile
             (hysterectomy, oophorectomy, or tubal ligation) or postmenopausal for &gt;1 year,

          3. Women of childbearing potential (WOCBP), expected to be using an acceptable method of
             contraception (sexual abstinence, implants, IUD, injectables, vasectomised partner or
             association of condom + spermicide, diaphragm + spermicide, diaphragm + condom) for a
             period of at least 1 month before and after dose administration. WOCBP were expected
             to have a negative pregnancy test (serum beta-human chorionic gonadotropin [β-HCG])
             result within 48 hours before the start of the first IMP administration. Hormonal
             contraceptives were not allowed because the effect of BIA 9-1067 on the metabolism of
             oral contraceptives and vice versa is not yet known,

          4. Male subjects should not have been planning to father a child or donate sperm, during
             the study and 1 month after the end of the study. Acceptable methods of contraception
             comprised condom and a medically accepted contraceptive method for the female partner
             (intra-uterine device with spermicide, hormonal contraceptive for the last 2 months),

          5. Expected to have a high probability for compliance with and completion of the study,
             Hepatic Impaired Patients only:

          6. Aged 18 to 65 years,

          7. Body weight ≥ 50 kg,

          8. Child Pugh class B (score at 7, 8 or 9) calculated according to the Child-Pugh
             classification based on history, physical examination, and laboratory test results at
             screening and on Day -1,

          9. Hepatic impairment should not have been associated to an underlying systemic disease,

         10. Medications necessary for the management of the hepatic disease or concomitant
             conditions were permitted if the therapeutic regimen has been stable for at least 7
             days before BIA 9-1067 administration and if they did not interfere with the kinetics
             of the tested product,

             Matched Healthy Subjects only:

         11. Aged 18 to 65 years,

         12. Body weight ≥ 50 kg,

         13. Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs, and 12-lead
             electrocardiogram (ECG). Alanine aminotransferase (ALT) and creatinine levels should
             have been strictly within the normal range for eligibility.

        Exclusion Criteria:

          1. Presence or history of any disorder that may prevent the successful completion of the
             study. Allergies and Adverse Drug Reactions

          2. History of multiple and/or severe allergies to drugs or foods or a history of
             anaphylactic reactions.

          3. Known or suspected allergy or other adverse drug reactions to the trial product or
             related products (e.g tolcapone or entacapone).

          4. Positive pregnancy test result (serum Beta-HCG) for women of childbearing potential
             only.

          5. Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or cola),
             grapefruit, grapefruit-containing products, or alcoholic beverages from 48 hours
             before study day 1 until the end of the inpatient confinement period.

          6. Involvement in other investigational studies of any type within 30 days of BIA 9-1067
             administration.

          7. Donation of blood within 90 days of study day 1.

          8. Evidence of unstable clinically significant disease other than impaired hepatic
             function (e.g., cardiovascular, cerebrovascular, respiratory, renal disease, or any
             serious disorder that currently requires a physician's care).

          9. Recent history or presence of any disorder that may interfere with the absorption,
             distribution, metabolism, or excretion of BIA 9-1067 (except hepatic impairment).

         10. Patients with severe encephalopathy.

         11. Acute exacerbation of hepatic disease, as indicated by worsening of clinical and/or
             laboratory signs of hepatic impairment, within the 2 weeks before BIA 9-1067
             administration (eg, advanced ascites, infection of ascites, fever, hepatic
             encephalopathy or active gastrointestinal bleeding (hematemesis, melena), significant
             abdominal pain, persistent nausea and vomiting, or a worsening of total bilirubin or
             prothrombin time by &gt;50%).

         12. Presence of a hepatocellular carcinoma, or an acute hepatic disease caused by
             infection or drug toxicity.

         13. Presence of surgically created portal-systemic shunt.

         14. Positive serologic finding for human immunodeficiency virus (HIV) antibodies.

         15. Prescription and over-the-counter (OTC) medication doses must be stable for 7 days
             before IMP administration.

             Healthy Matched Subjects only:

         16. History of alcoholism or excessive daily alcohol consumption within the past year.
             Excessive alcohol consumption is regarded as an average weekly intake of more than 14
             units for women and 21 units for men (1 unit of alcohol = 8 to 10 g and is
             approximately equivalent to 1 glass of wine or 250 mL of beer or a standard measure of
             spirits).

         17. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

         18. Any clinically important deviation from normal limits in physical examination, vital
             signs, or 12-lead ECGs.

         19. Acute disease state (e.g., nausea, vomiting, fever, diarrhea) within 7 days of study
             day 1.

         20. Positive serologic findings for HIV antibodies, hepatitis B surface antigen (Hbs Ag),
             and/or hepatitis C virus (HCV) antibodies.

         21. Recent history or presence of any disorder that may interfere with the absorption,
             distribution, metabolism, or excretion of BIA 9-1067.

         22. Use of any prescription drug within 30 days of IMP administration.

         23. Use of any OTC drugs including herbal supplements (except for the occasional use of
             acetaminophen and vitamins ≤100% recommended daily allowance) within 14 days of study
             day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricio Soares-da-Silva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BIAL - Portela &amp; Cª, S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotrial, 7-9 rue Jean-Louis Bertrand</name>
      <address>
        <city>Rennes</city>
        <zip>F-35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City clinical Hospital N°64</name>
      <address>
        <city>Moscow</city>
        <zip>17292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City clinical Hospital N°3</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>January 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2015</results_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BIA 9-1067</keyword>
  <keyword>Opicapone</keyword>
  <keyword>catechol-O-methyltransferase (COMT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Hepatic Impaired Subjects</title>
          <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Healthy Subjects</title>
          <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Hepatic Impaired Subjects</title>
          <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Healthy Subjects</title>
          <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration of BIA 9-1067</title>
        <description>BIA 9-1067 Cmax following a single dose of 50mg BIA 9-1067</description>
        <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Hepatic Impaired Subjects</title>
            <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Healthy Subjects</title>
            <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Plasma Concentration of BIA 9-1067</title>
          <description>BIA 9-1067 Cmax following a single dose of 50mg BIA 9-1067</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1108" spread="448"/>
                    <measurement group_id="O2" value="559" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Reach Cmax</title>
        <description>BIA 9-1067 Tmax following a single dose of 50mg BIA 9-1067</description>
        <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Hepatic Impaired Subjects</title>
            <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Healthy Subjects</title>
            <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Reach Cmax</title>
          <description>BIA 9-1067 Tmax following a single dose of 50mg BIA 9-1067</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC0-t)</title>
        <description>BIA 9-1067 AUC0-t following a single dose of 50mg BIA 9-1067</description>
        <time_frame>pre-dose (within 1 hour before dose administration) and then at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Hepatic Impaired Subjects</title>
            <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Healthy Subjects</title>
            <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-t)</title>
          <description>BIA 9-1067 AUC0-t following a single dose of 50mg BIA 9-1067</description>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3392" spread="1584"/>
                    <measurement group_id="O2" value="1724" spread="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Hepatic Impaired Subjects</title>
          <description>Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Healthy Subjects</title>
          <description>Group 2 - healthy subjects treated with BIA 9-1067
BIA 9-1067: Opicapone, OPC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

